Therapeutic Advancement in Cardiovascular Disorders: Molecular Mechanisms, Emerging Targets and Translational Perspectives
Abstract
Cardiovascular disorders (CVD) have been addressed as the leading cause of global mortality and morbidity which majorly includes atherosclerosis, hypertension, heart failure, arrhythmias and cardiomyopathies. Its pathogenesis involves various interconnected molecular mechanisms such as endothelial dysfunction, oxidative stress, chronic inflammation, mitochondrial impairment, lipid dysregulation, fibrosis and genetic alterations. The conventional pharmacological strategy of CVD includes statins, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers and antiplatelet agents. Clinically, though these medications have provided substantial improved outcomes but its long-term usage has been frequently associated with drug resistance, hepatotoxicity, myopathy, renal dysfunction, bleeding risk and residual cardiovascular events. Moreover, these primarily target symptomatic and hemodynamic abnormalities rather than the underlying molecular pathology. Recent advances in molecular cardiology and translational medicine have facilitated the development of targeted therapeutic strategies that primarily aims to overcome these limitations. Specifically, targeting dysregulated lipid pathophysiology, stains utilization has evolved to PCSK9 inhibitors and small interfering RNA (siRNA)-based therapeutics, such as inclisiran. Precision medication strategy has made the use of RNA therapeutics and CRISPR-Cas9-mediated which enable precise regulation of disease-associated genes. Regenerative stem cell therapies, on the other hand promoted myocardial repair and angiogenesis, while nanotechnology-based drug delivery systems improved therapeutic specificity and bioavailability. In parallel to this, AI-assisted precision cardiology has enabled early diagnosis, risk stratification, and individualized treatment planning strategies. However, despite these advances, challenges related to safety, delivery efficacy, ethical concerns and expense remain the major barriers to widespread clinical translation of these therapeutic advancements in cardiac patients.
Keywords: Cardiovascular disorders, Conventional cardiac-therapeutics, PCSK9 inhibitors
Keywords:
Cardiovascular Disorders, Conventional cardiac-therapeutics, PCSK9 inhibitors, RNA-based therapeutics, Gene editing, Stem-cell therapy, Nanotechnology, Precision cardiologyDOI
https://doi.org/10.22270/jddt.v16i7.7825References
1. WHO. Cardiovascular diseases [Internet]. [cited 2026 May 27]. Available from: https://www.who.int/health-topics/cardiovascular-diseases
2. Ghodeshwar GK, Dube A, Khobragade D. Impact of Lifestyle Modifications on Cardiovascular Health: A Narrative Review. Cureus. 15(7):e42616. doi:10.7759/cureus.42616 PubMed PMID: 37641769;
3. Frąk W, Wojtasińska A, Lisińska W, Młynarska E, Franczyk B, Rysz J. Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease. Biomedicines. 2022 Aug 10;10(8):1938. PMC9405799. https://doi.org/10.3390/biomedicines10081938 PMid:36009488
4. Foëx P. Innovations in management of cardiac disease: drugs, treatment strategies and technology. British Journal of Anaesthesia. 2017 Dec 1;119:i23-33. https://doi.org/10.1093/bja/aex327 PMid:29161389
5. Netala VR, Teertam SK, Li H, Zhang Z. A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells. 2024 Sep 1;13(17):1471.https://doi.org/10.3390/cells13171471 PMid:39273041
6. Addissouky TA, Sayed IETE, Ali MMA, Alubiady MHS, Wang Y. Recent developments in the diagnosis, treatment, and management of cardiovascular diseases through artificial intelligence and other innovative approaches. J Biomed Res. 2024 Mar 12;Volume 5(Issue 1):29-40. https://doi.org/10.46439/biomedres.5.041
7. Ajoolabady A, Pratico D, Lin L, Mantzoros CS, Bahijri S, Tuomilehto J, et al. Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell Death Dis. 2024 Nov 11;15(11):817. PMCid:PMC11555284 https://doi.org/10.1038/s41419-024-07166-8 PMid:39528464
8. Pahwa R, Jialal I. Atherosclerosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. PubMed PMID: 29939576. http://www.ncbi.nlm.nih.gov/books/NBK507799/
9. Harrison DG, Coffman TM, Wilcox CS. Pathophysiology of Hypertension. Circulation Research. 2021 Apr 2;128(7):847-63. https://doi.org/10.1161/CIRCRESAHA.121.318082 PMid:33793328 PMCid:PMC8023760
10. Chen FY, Lee CW, Chen YJ, Lin YH, Yeh CF, Lin CC, et al. Pathophysiology and blood pressure measurements of hypertension in the elderly. Journal of the Formosan Medical Association. 2025 Jul 1;Elderly Hypertension124:S10-6. https://doi.org/10.1016/j.jfma.2025.03.027 PMid:40328594
11. Deepshikha null, Mathur P, Monika null, Jhawat V, Shekhar S, Dutt R, et al. An Overview of Hypertension: Pathophysiology, Risk Factors, and Modern Management. Curr Hypertens Rev. 2025;21(2):64-81. https://doi.org/10.2174/0115734021349254250224074832 PMid:40051353
12. Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):263-76. https://doi.org/10.21037/cdt-20-302 PMid:33708498 PMCid:PMC7944197
13. Mann DL, Felker GM. Mechanisms and Models in Heart Failure. Circulation Research. 2021 May 14;128(10):1435-50. https://doi.org/10.1161/CIRCRESAHA.121.318158 PMid:33983832 PMCid:PMC8130816
14. Keating MT, Sanguinetti MC. Molecular and Cellular Mechanisms of Cardiac Arrhythmias. Cell. 2001 Feb 23;104(4):569-80. https://doi.org/10.1016/S0092-8674(01)00243-4 PMid:11239413
15. Wilde AAM, Bezzina CR. Genetics of cardiac arrhythmias. Heart. 2005 Oct;91(10):1352-8. https://doi.org/10.1136/hrt.2004.046334 PMid:16162633 PMCid:PMC1769155
16. Lopes LR, Ho CY, Elliott PM. Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice. Eur Heart J. 2024 Aug 7;45(30):2727-34. https://doi.org/10.1093/eurheartj/ehae421 PMid:38984491 PMCid:PMC11313585
17. Hespe S, Waddell A, Asatryan B, Owens E, Thaxton C, Adduru ML, et al. Genes Associated With Hypertrophic Cardiomyopathy: A Reappraisal by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel. Journal of the American College of Cardiology. 2025 Feb 25;Special Focus Issue: Heart Failure85(7):727-40. https://doi.org/10.1016/j.jacc.2024.12.010 PMid:39971408 PMCid:PMC12079304
18. Eldemire R, Mestroni L, Taylor MRG. Genetics of Dilated Cardiomyopathy. Annu Rev Med. 2024 Jan 29;75:417-26. doi:10.1146/annurev-med-052422-020535 PubMed PMID: 37788487; PubMed Central PMCID: PMC10842880. https://doi.org/10.1146/annurev-med-052422-020535 PMid:37788487 PMCid:PMC10842880
19. Mazzanti A, Kukavica D, Trancuccio A, Scilabra GG, Coppini L, Pergola V, et al. Genetics in arrhythmogenic cardiomyopathies: where are we now and where are we heading to? Eur Heart J Suppl. 2025 Feb 1;27(Supplement_1):i98-102. https://doi.org/10.1093/eurheartjsupp/suae114 PMid:39980788 PMCid:PMC11836680
20. Gerull B, Brodehl A. Insights Into Genetics and Pathophysiology of Arrhythmogenic Cardiomyopathy. Curr Heart Fail Rep. 2021;18(6):378-90. PubMed PMID: 34478111; PubMed Central PMCID: PMC8616880. https://doi.org/10.1007/s11897-021-00532-z PMid:34478111 PMCid:PMC8616880
21. Kessler T, Schunkert H. Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies. JACC: Basic to Translational Science. 2021 Jul;6(7):610-23. https://doi.org/10.1016/j.jacbts.2021.04.001 PMid:34368511 PMCid:PMC8326228
22. Shehjar F, Mahajan R, Shahnaz S, Shah ZA. Genetic and epigenetic architectures of stroke: Insights from GWAS to precision medicine. Neurochemistry International. 2025 Nov 1;190:106059. https://doi.org/10.1016/j.neuint.2025.106059 PMid:41005670 PMCid:PMC13261748
23. Yoshimoto T, Yamagami H, Matsumaru Y. Recent Advances in Stroke Genetics-Unraveling the Complexity of Cerebral Infarction: A Brief Review. Genes. 2025 Jan 6;16(1). https://doi.org/10.3390/genes16010059 PMid:39858606 PMCid:PMC11764629
24. Kullo IJ, Leeper NJ. The Genetic Basis of Peripheral Arterial Disease: Current Knowledge, Challenges and Future Directions. Circ Res. 2015 Apr 24;116(9):1551-60. https://doi.org/10.1161/CIRCRESAHA.116.303518 PMid:25908728 PMCid:PMC4410432
25. Ochoa Chaar CI, Kim T, Alameddine D, DeWan A, Guzman R, Dardik A, et al. Systematic review and meta-analysis of the genetics of peripheral arterial disease. JVS Vasc Sci. 2024;5:100133. https://doi.org/10.1016/j.jvssci.2023.100133 PMid:38314202 PMCid:PMC10832467
26. Gladwell LR, Ahiarah C, Rasheed S, Rahman SM, Choudhury M. Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both? Life (Basel). 2023 Dec 22;14(1):23. https://doi.org/10.3390/life14010023 PMid:38255639 PMCid:PMC10820772
27. Ramkumar S, Raghunath A, Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin. 2016 Nov;32(6):631-9. doi:10.6515/ACS20160611A PubMed PMID: 27899849;
28. Chhetry M, Jialal I. Lipid-Lowering Drug Therapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Jun 11]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK541128/ PubMed PMID: 31082172.
29. Kypreos KE, Bitzur R, Karavia EA, Xepapadaki E, Panayiotakopoulos G, Constantinou C. Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. Angiology. 2019 Mar 1;70(3):197-209. https://doi.org/10.1177/0003319718779533 PMid:29862840
30. Khalil H, Zeltser R. Antihypertensive Medications. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 May 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554579/ PubMed PMID: 32119466.
31. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST. 2012 Feb 1;141(2):e89S-e119S. 22315278. https://doi.org/10.1378/chest.11-2293 PMid:22315278 PMCid:PMC3278069
32. Bikdeli B, Ujueta F, Rashedi S, Talasaz AH, Kadakia KT, Lopes RD, et al. Antiplatelet and Anticoagulant Therapy in the 2025 ACC/AHA Guideline for Acute Coronary Syndromes. JACC. 2025 Jun 10;85(22):2074-8. https://doi.org/10.1016/j.jacc.2025.04.002 PMid:40467132
33. Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. European Heart Journal. 2023 May 22;44(31):2893. https://doi.org/10.1093/eurheartj/ehad347 PMid:37216684 PMCid:PMC10424879
34. Scranton K, John S, Angelini M, Zhang R, Schwingshackl A, Goldhaber JI, et al. The mechanism of action of digoxin requires the sodium-dependent inactivation of the sodium-calcium exchanger. Science Advances. 2025 Dec 17;11(51):eady9596. https://doi.org/10.1126/sciadv.ady9596 PMid:41406234 PMCid:PMC12710698
35. Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport 2 (SGLT2) Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 May 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK576405/ PubMed PMID: 35015430.
36. Allam M, Akowuah E. Common cardiac surgical procedures: bypass, valve repair and replacement. Surgery (Oxford). 2024 Feb 1;Cardiothoracic Surgery - I42(2):98-105. https://doi.org/10.1016/j.mpsur.2023.12.013
37. Szlapka M, Hetzer R, Ennker J, Hausmann H. Conventional cardiac surgery in patients with end-stage coronary artery disease: yesterday and today. Cardiovascular Diagnosis and Therapy. 2021 Feb;11(1):20212-20212. https://doi.org/10.21037/cdt-20-284 PMid:33708493 PMCid:PMC7944224
38. Massera D, Sherrid MV, Scheinerman JA, Swistel DG, Razzouk L. Medical, Surgical, and Interventional Management of Hypertrophic Cardiomyopathy. Circ: Cardiovascular Interventions. 2025 Mar;18(3). https://doi.org/10.1161/CIRCINTERVENTIONS.124.014023 PMid:39925290
39. Doenst T, Kirov H, Bagiella E, Scherag A, Omerovic E. Challenges of conventional and novel approaches to clinical trial designs in cardiovascular medicine. Eur J Cardiothorac Surg. 2025 Mar 4;67(3):ezaf056. https://doi.org/10.1093/ejcts/ezaf056 PMid:39980154
40. Townsend N, Timmis A, Erglis A, Miličić D, Perrone-Filardi P, Weidinger F, et al. Challenges in the prevention, treatment and management of cardiovascular disease among older adults. Lancet Reg Health Eur. 2025 Aug 21;56:101372. https://doi.org/10.1016/j.lanepe.2025.101372 PMid:41200013 PMCid:PMC12587328
41. Addissouky TA, Sayed IETE, Ali MMA, Alubiady MHS, Wang Y. Recent developments in the diagnosis, treatment, and management of cardiovascular diseases through artificial intelligence and other innovative approaches. J Biomed Res. 2024 Mar 12;Volume 5(Issue 1):29-40. https://doi.org/10.46439/biomedres.5.041
42. Strandberg TE. Benefits and limitations of statin use in primary cardiovascular prevention: recent advances. Pol Arch Intern Med. 2022 May 30;132(5):16258. PubMed PMID: 35635404. https://doi.org/10.20452/pamw.16258 PMid:35635404
43. Xu J, Shapiro MD. Current Evidence and Future Directions of PCSK9 Inhibition. US Cardiol. 2021 Feb 16;15:e01. https://doi.org/10.15420/usc.2020.17 PMid:39720497 PMCid:PMC11664773
44. Furtado RHM, Giugliano RP. What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. Cardiol Ther. 2020 Jun;9(1):59-73. https://doi.org/10.1007/s40119-020-00163-w PMid:32026310 PMCid:PMC7237602
45. Blom DJ, Marais AD, Moodley R, van der Merwe N, van Tonder A, Raal FJ. RNA-based therapy in the management of lipid disorders: a review. Lipids Health Dis. 2022 Apr 23;21(1):41. https://doi.org/10.1186/s12944-022-01649-3 PMid:35459248 PMCid:PMC9034497
46. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine. 2020 Apr 16;382(16):1507-19. https://doi.org/10.1056/NEJMoa1912387 PMid:32187462
47. Bhatia HS, Bajaj A, Goonewardena SN, Moriarty PM. Pelacarsen: Mechanism of action and Lp(a)-lowering effect. Journal of Clinical Lipidology. 2025 Sep 1;19(5):1208-22. https://doi.org/10.1016/j.jacl.2025.06.004 PMid:40781022
48. Tweneboah C, Kaur G. Lowering of Lipoprotein(a) with Olpasiran. Cardiovasc Hematol Disord Drug Targets. 2026 Mar 23. https://doi.org/10.2174/011871529X428489260113103704 PMid:41879443
49. Pande S. CRISPR-Cas9 gene therapy in dyslipidemia: a leap into the future? Postgrad Med J. 2026 Feb 25;qgag019. doi:10.1093/postmj/qgag019 https://doi.org/10.1093/postmj/qgag019 PMid:41739631
50. Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement. JACC. 2026 Mar 24;87(11):1381-404. https://doi.org/10.1016/j.jacc.2025.08.047 PMid:41020749
51. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017 Sep 21;377(12):1119-31. https://doi.org/10.1056/NEJMoa1707914 PMid:28845751
52. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020 Nov 4;383(19):1838-47. https://doi.org/10.1056/NEJMoa2021372 PMid:32865380 PMCid:PMC11530513
53. Huang S, Frangogiannis NG. Anti‐inflammatory therapies in myocardial infarction: failures, hopes and challenges. Br J Pharmacol. 2018 May;175(9):1377-400. https://doi.org/10.1111/bph.14155 PMid:29394499 PMCid:PMC5901181
54. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet. 2020 Sep 19;396(10254):819-29. https://doi.org/10.1016/S0140-6736(20)31824-9 PMid:32877652 PMCid:PMC9668858
55. Mao Y an, Shi X, Sun P, Spanos M, Zhu L, Chen H, et al. Nanomedicines for cardiovascular diseases: Lessons learned and pathways forward. Biomaterials. 2025 Sep 1;320:123271. https://doi.org/10.1016/j.biomaterials.2025.123271 PMid:40117750
56. Safhi AY, Albariqi AH, Sabei FY, Alsalhi A, Khalil FMA, Waheed A, et al. Journey into tomorrow: cardiovascular wellbeing transformed by nano-scale innovations. Current Problems in Cardiology. 2024 Apr 1;49(4):102428. https://doi.org/10.1016/j.cpcardiol.2024.102428 PMid:38311274
57. Lima ES, Santos D dos, Souza AL, Macedo ME, Bandeira ME, Junior SSS, et al. RNA Combined with Nanoformulation to Advance Therapeutic Technologies. Pharmaceuticals. 2023 Nov 21;16(12). doi:10.3390/ph16121634 https://doi.org/10.3390/ph16121634 PMid:38139761 PMCid:PMC10745936
58. Zhang S, Han M, Li S, Wang Y, Wu L, Dong L, et al. Platelet-derived biomimetic nanoplatforms: a promising drug delivery strategy for cardiovascular disease. J Nanobiotechnol. 2025 Oct 21;23(1):687. https://doi.org/10.1186/s12951-025-03700-8 PMid:41121084 PMCid:PMC12542209
59. Wu Y, Vazquez-Prada KX, Liu Y, Whittaker AK, Zhang R, Ta HT. Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases. Nanotheranostics. 2021 Jul 21;5(4):499-514. https://doi.org/10.7150/ntno.62730 PMid:34367883 PMCid:PMC8342263
60. Goto T, Nakamura Y, Ito Y, Miyagawa S. Regenerative medicine in cardiovascular disease. Regenerative Therapy. 2024 Jun 1;26:859-66. https://doi.org/10.1016/j.reth.2024.09.004 PMid:39430582 PMCid:PMC11490749
61. Razavi ZS, Farokhi S, Mahmoudvand G, Karimi-Rouzbahani A, Farasati-Far B, Tahmasebi-Ghorabi S, et al. Stem cells and bio scaffolds for the treatment of cardiovascular diseases: new insights. Front Cell Dev Biol. 2024 Dec 12;12. https://doi.org/10.3389/fcell.2024.1472103 PMid:39726717 PMCid:PMC11669526
62. Idhrees M, Zainulabedin H, Varun G. The interventional cardiovascular surgeon-the future. Indian J Thorac Cardiovasc Surg. 2024 Jan;40(1):116-8. https://doi.org/10.1007/s12055-023-01653-x PMid:38125326 PMCid:PMC10728418
63. Leon MB, Mack MJ, Pibarot P, Hahn RT, Thourani VH, Kodali SH, et al. Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years. New England Journal of Medicine. 2026 Feb 18;394(8):773-83. https://doi.org/10.1056/NEJMoa2509766 PMid:41144631
64. Salgado RA, Budde RPJ, Leiner T, Shivalkar B, Van Herck PL, Op de Beeck BJ, et al. Transcatheter aortic valve replacement: postoperative CT findings of Sapien and CoreValve transcatheter heart valves. Radiographics. 2014 Oct;34(6):1517-36. PubMed PMID: 25310415. https://doi.org/10.1148/rg.346130149 PMid:25310415
65. Bonatti J, Vetrovec G, Riga C, Wazni O, Stadler P. Robotic technology in cardiovascular medicine. Nat Rev Cardiol. 2014 May;11(5):266-75. https://doi.org/10.1038/nrcardio.2014.23 PMid:24663088
66. Luo X, Pang Z, Li J, Anh M, Kim BS, Gao G. Bioengineered human arterial equivalent and its applications from vascular graft to in vitro disease modeling. iScience. 2024 Nov 15;27(11):111215. https://doi.org/10.1016/j.isci.2024.111215 PMid:39555400 PMCid:PMC11565542
67. Razavi ZS, Farokhi S, Mahmoudvand G, Karimi-Rouzbahani A, Farasati-Far B, Tahmasebi-Ghorabi S, et al. Stem cells and bio scaffolds for the treatment of cardiovascular diseases: new insights. Front Cell Dev Biol. 2024 Dec 12;12:1472103. . https://doi.org/10.3389/fcell.2024.1472103 PMid:39726717 PMCid:PMC11669526
68. Li R. Advancements and Future Directions in Cardiovascular and Vascular Surgeries. JSM Atherosclerosis. 2024 Jul 29;5(1):1-2. doi:10.47739/2573-1270/1045
69. Kishimoto S, Higashi Y. Recent advances and emerging perspectives in vascular and cardiovascular research: A 2025 update. Hypertens Res. 2026 Mar;49(3):740-8. https://doi.org/10.1038/s41440-025-02540-1 PMid:41514023 PMCid:PMC12960199
70. Wawage DS, Devasena DI, Parate DV, Singh DA. Innovations in Cardiovascular Disease Prevention: Systematic Review. European Journal of Cardiovascular Medicine [Internet]. 2024 Dec 16 [cited 2026 May 28];14:587-91. Available from: https://healthcare-bulletin.co.uk/article/innovations-in-cardiovascular-disease-prevention-systematic-review--2634/
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Shibani Jena, Shailaja Lenka , Chetna Patra , Sanjay Kumar Raul
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.